Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

mTOR inhibitors vs chemotherapy/hormone therapy

Progression‐free survival · women with advanced or recurrent endometrial cancer

mTOR inhibitors may leads to higher progression‐free survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 1.43 [1.06, 1.93]
1 study · 231 participants
Low

EGFR tyrosine kinase inhibitor (TKI) vs observation

Progression‐free survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 1.05 [0.9, 1.23]
1 study · 835 participants
Very low